COMPANY

Jabez Biosciences

Jabez is advancing a focused pipeline of rational, synergistic cancer therapies: beginning with JBZ-001, an oral DHODH inhibitor currently in Phase 1 clinical development. From company website Source · Oct 12, 2026

Keywords: clinical development cancer

Profile checked Oct 10, 2026

Funding and NIH signals

SEC Form D raise Form D reports $31K sold since 2024 (filed Mar 26, 2026); +2 other Form D filings in the last 12 months. SEC Form D 0001213900-26-034473 (Mar 26, 2026)
Evidence (3 events)
- Mar 26, 2026 · SEC Form D 0001213900-26-034473
  Name of Issuer: Jabez Biosciences, Inc.; CIK: 2038185; Address: Cranberry Twp., PA; Submission type: D; Filing date: 2026-03-26; Industry Group: Biotechnology; Date of First Sale: 2024-06-11; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 31200; Federal exemptions: 06b
- Oct 21, 2025 · SEC Form D 0001213900-25-100745
  Name of Issuer: Jabez Biosciences, Inc.; CIK: 2038185; Address: Cranberry Twp., PA; Submission type: D; Filing date: 2025-10-21; Industry Group: Biotechnology; Date of First Sale: 2024-11-11; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 2550000; Federal exemptions: 06b || Name of Issuer: Jabez Biosciences, Inc.; CIK: 2038185; Address: Cranberry Twp., PA; Submission type: D/A; Filing date: 2025-10-28; Industry Group: Biotechnology; Date of First Sale: 2024-11-11; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 250510; Federal exemptions: 06b
- Oct 21, 2025 · SEC Form D 0001213900-25-100637
  Name of Issuer: Jabez Biosciences, Inc.; CIK: 2038185; Address: Cranberry Twp., PA; Submission type: D; Filing date: 2025-10-21; Industry Group: Biotechnology; Date of First Sale: 2024-08-07; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 3000000; Total Amount Sold: 1326500; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals